Updated:
BigHat Biosciences
BigHat Biosciences designs antibody therapies using ML-guided design and synthetic biology.
BigHat Biosciences
BigHat Biosciences operates out of San Mateo, California, as a Series B biotech company focused on antibody discovery and engineering. The firm does not publicly disclose its founding year or a named founder, but positions itself as an interdisciplinary team of scientists and engineers. The firm's Milliner platform combines synthetic biology-based high-speed wet-lab characterization with machine learning to design safer, more effective antibody therapies. BigHat targets challenging diseases including infections and cancers through wholly-owned and partnered programs. Confirmed investors include top-tier VCs, though specific names are not disclosed on the firm website. Geographic focus is primarily North America. BigHat has raised over $100M from institutional investors, per the firm website. The team comprises experts in machine learning, software engineering, automation, synthetic biology, genetics, and molecular biology. The firm maintains a culture of work/life balance and family-friendly policies, though it does not disclose adjacent vehicles like foundations or club memberships. A structural differentiator is BigHat's full-stack integration of wet-lab and ML into a single weekly workcell, enabling characterization of hundreds of recombinant antibodies per cycle. This approach aims to accelerate the timeline from target identification to clinical candidate compared to traditional biotech models.
General information
Firm type
Asset Manager
Year founded
—
AUM
Undisclosed
Location
Region
North America
Country
United States
City
San Mateo
Corporate office
San Mateo, CA, United States
Sector focus
Frequently asked questions
Who runs investment decisions at BigHat Biosciences?
BigHat does not publicly name its CEO or investment team on its website. The firm describes itself as led by experienced leaders and world-class advisors, but does not list individual names or titles.
How does BigHat source its therapeutic programs?
BigHat develops its own wholly-owned pipeline and also engages in research collaborations and drug development partnerships with strategic partners (per firm website). The firm's Milliner platform generates proprietary antibody candidates.
Is BigHat structured as a venture-funded biotech or a family office?
BigHat is a venture-backed biotech company, not a family office. It has raised over $100M in Series B funding from institutional investors and operates as a corporation, not an investment vehicle for a single family.
Does BigHat participate in fund commitments or only direct deals?
BigHat does not act as an investment fund. It uses its own capital and partner funding to advance its internal therapeutic programs and collaborations. It does not appear to make external fund commitments.
What investment stages does BigHat typically target?
BigHat focuses on early-stage drug discovery and preclinical development of antibody therapies. Its pipeline is wholly-owned and partnered, targeting stages from target identification to clinical candidate selection.
Which sectors does BigHat explicitly avoid?
BigHat's website does not list sectors it avoids. Its disclosed focus is on antibody therapies for challenging diseases, particularly infections and cancers.
How is BigHat related to its investors?
BigHat does not name its investors on its website, but describes them as top-tier institutional groups. The firm operates independently, with investors providing capital rather than operational control.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: